



COVID-19: KEEPING UP WITH A MOVING TARGET

Aug 12, 2020 UPDATE



Paul Auwaerter, MD, MBA, FIDSA
Clinical Director, Division of Infectious Diseases
Sherrilyn and Ken Fisher Professor of Medicine
Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine



Postgraduate Institute
for Medicine



JOHNS HOPKINS
NURSING

CME Information

Jointly provided by Postgraduate Institute for Medicine, DKBmed, and the Institute for Johns Hopkins Nursing.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

| Name of Faculty or Presenter | Reported Financial Relationship |
|-----------------------------------|--|
| Paul G. Auwaerter, MD, MBA, FIDSA | Scientific Advisor: DiaSorin, Shionogi Inc. JNJ: Ownership equity |

Dr. Auwaerter has indicated that he will be referencing the unlabeled or unapproved use of agents currently being investigated in on-going studies and trials. These include COVID-19 convalescent plasma and vaccine platforms.

All activity, content, and materials have been developed solely by the activity directors, planning committee members, and faculty presenters, and are free of influence from a commercial entity.





CME Information

To attest for CME/CE/AAPA credit, please visit
COVID19.dkbmed.com





Learning Objectives

- Describe data pertaining to study of olfactory symptoms discussed in this webinar
- Discuss findings of interview-based study of symptom duration in nonhospitalized people with COVID
- Describe preliminary data of the observational study of convalescent plasma





Thank You

This activity is supported by an educational grant from Pfizer, Inc. and in-kind support by DKBmed, LLC.

All activity content and materials have been developed solely by the activity directors, planning committee members, and faculty presenters.

Please see **COVID19.DKBmed.com** for additional resources and educational activities





Paul Auwaerter, MD, MBA, FIDSA
Clinical Director, Division of Infectious Diseases
Sherrilyn and Ken Fisher Professor of Medicine
Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine





Total Global Cases (8/12/20)

coronavirus.jhu.edu/map.html



COVID Trends, US

Confirmed cases
5,092,519
 (Yesterday: +49,536)


Deaths
163,396
 (Yesterday: +525)

Deaths per capita Cases per capita **Increase in cases**

There are currently 5,092,519 cases confirmed in the US. Yesterday, it increased by 49,536, or 1.0%¹


Increase in total cases since last week

- Less than 5% increase
- More than 5% increase
- More than 15% increase
- More than 30% increase



Last updated: 11 Aug 8:25am EST

United States Trends in Emergency Department Visits



CDC COVID-19 tracker

<https://www.theguardian.com/world/ng-interactive/2020/jul/15/covid-19-coronavirus-us-map-latest-cases-state-by-state>




COVID-19 and Smell/Taste

Journal of Otolaryngology - Head & Neck Surgery

[Home](#) [About](#) [Articles](#) [Submission Guidelines](#) [Highlights](#)

Original research article | [Open Access](#) | [Published: 06 August 2020](#)

Do olfactory and gustatory psychophysical scores have prognostic value in COVID-19 patients? A prospective study of 106 patients

[Luigi Angelo Vaira](#), [Claire Hopkins](#) , [Marzia Petrocelli](#), [Jerome R. Lechien](#), [Damiano Soma](#), [Federica Giovanditto](#), [Davide Rizzo](#), [Giovanni Salzano](#), [Pasquale Piombino](#), [Sven Saussez](#) & [Giacomo De Riu](#)

Journal of Otolaryngology - Head & Neck Surgery **49**, Article number: 56 (2020) | [Cite this article](#)

84 Accesses | [Metrics](#)

Study from Bologna, Italy

N = 106 patients, adults
< 4d of COVID-19 symptoms

20 d observation: olfactory, gustatory evaluations at d0, d10, and d20

67% with olfactory impairment
65.6% gustatory dysfunction

Findings:

- Initial olfactory/gustatory ≠ prognostic value
- Persistent olfactory impairment day 20 associated with more severe disease and hospitalization



COVID-19 Symptom Duration



[A-Z Index](#)

[Advanced Search](#)

Morbidity and Mortality Weekly Report (MMWR)

CDC



Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020

Weekly / July 31, 2020 / 69(30):993-998

On July 24, 2020, this report was posted online as an MMWR Early Release.

Mark W. Tenforde, MD, PhD¹; Sara S. Kim, MPH^{1,2}; Christopher J. Lindsell, PhD³; Erica Billig Rose, PhD¹; Nathan I. Shapiro, MD⁴; D. Clark Files, MD⁵; Kevin W. Gibbs, MD⁵; Heidi L. Erickson, MD⁵; Jay S. Steingrub, MD⁷; Howard A. Smithline, MD⁷; Michelle N. Gong, MD⁸; Michael S. Aboodi, MD⁸; Matthew C. Exline, MD⁹; Daniel J. Henning, MD¹⁰; Jennifer G. Wilson, MD¹¹; Akram Khan, MD¹²; Nida Qadir, MD¹³; Samuel M. Brown, MD¹⁴; Ithan D. Peltan, MD¹⁴; Todd W. Rice, MD³; David N. Hager, MD, PhD¹⁵; Adit A. Ginde, MD¹⁶; William B. Stubblefield, MD³; Manish M. Patel, MD¹; Wesley H. Self, MD³; Leora R. Feldstein, PhD¹; IVY Network Investigators; CDC COVID-19 Response Team ([View author affiliations](#))

274 interviewees, 13 states
94% symptomatic at time of testing





Symptoms after mild COVID-19

- 35% not at usual state of health by the date of the interview (median = 16 days from testing date)
 - 18-34 yrs: 26%
 - 35-49 yrs: 32%
 - ≥ 50 yrs: 50%
 - If cough (43%), fatigue (35%) or shortness of breath (29%)
- Older age and comorbidities also longer for hospitalized patients
- Limitations: survey, no assessment of pre-morbid functioning, more severely ill not answer telephone (?)
- Conclusions: more like infectious mononucleosis than common cold





Treatment





Convalescent Plasma Treatment

- Preliminary data (webinar 8/4/20)—
 - <https://cveducation.mayo.edu/lp/videos?vid=41>
- Large observational data (Joyner, et al) from eIND
 - ~3,000 patients
 - If received high titer convalescent plasma, 50% reduction in mortality at 7d
 - Patients with ≤ 3 d from symptom onset = mortality 6.6% (at 7d) v. 13.3% (≥ 4 d of symptoms and low titer plasma)
 - 30d mortality reduction: 36%





Convalescent Plasma Treatment

- Impressions:
 - Earlier administration for severe COVID-19 requiring hospitalization and oxygen is beneficial
 - Historically, beneficial for influenza (1918 pandemic, Ebola, others)
 - Not an RCT (missed opportunity this spring) for treatment
 - International effort to pool any convalescent plasma RCT data underway
- FDA may authorize by EUA






Prevention



Vaccine concerns

Coronavirus Vaccine Tracker

By Jonathan Corum, Denise Grady, Sui-Lee Wee and Carl Zimmer Updated August 11, 2020



Russian vaccine works ‘effectively enough,’ President Putin said. But it hasn’t completed Phase III tests.

A Russian health care regulator has become [the first in the world to approve a vaccine for the coronavirus](#), President Vladimir V. Putin announced on Tuesday, though the vaccine has yet to complete clinical trials.

- Adenovirus-based, S protein insert
- Researchers self-tested vaccine before human trials
- Said to have no safety events (n=76, June 2020)
- Given to 50 military personnel
- WHO lists this vaccine as in Phase 1
- Will start using the vaccine (HCWs, teachers)
- Phase III trial still planned





To submit your own question, please email QA@dkbmed.com





Is there any news on outpatient treatment? Are any asthma medications helpful?





With flu season around the corner and so many symptoms that appear to overlap, how should we manage patients with fever, headache, and myalgia?





What does the data say about long-term consequences of COVID-19?





To receive CME/CE/AAPA credit:

- Complete the evaluation on at COVID19.DKBmed.com
- Upon registering and successfully completing the activity evaluation, you will have immediate access to your certificate.

To access more resources related to COVID-19:

- Access our resource hub at COVID19.DKBmed.com

To ask your own question, email: QA@dkbmed.com

